

Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the  
CorEvitas Psoriasis Registry

Benjamin Lockshin, MD<sup>1</sup>, Ryan W. Harrison, MS<sup>2</sup>, Robert R. McLean DSc, MPH<sup>2</sup>, Margaux M. Crabtree,  
MPH<sup>2</sup>, Bruce W. Konicek, MS<sup>3</sup>, Baojin Zhu, PhD<sup>3</sup>, William N. Malatestinic, PharmD, MBA<sup>3</sup>, Bilal Atiya,  
PharmD<sup>3</sup>, Mwangi J. Murage, PhD, MPH<sup>3</sup>, Russel Burge, PhD<sup>3</sup>

<sup>1</sup>US Dermatology Partners, Rockville, MD, USA; <sup>2</sup>CorEvitas, LLC, Waltham, MA, USA; <sup>3</sup>Eli Lilly and  
Company, Indianapolis, IN, USA

Corresponding Author:

Benjamin Lockshin, MD  
US Dermatology Partners  
15245 Shady Grove Road, Suite 480  
Rockville, MD 20850  
(301) 681-7397  
blockshin@dermassociates.com

**Supplemental Table 1. Estimated Percent Achievement**

Outcome	Unadjusted		Adjusted*	
	SEC	OTH BIO	SEC	OTH BIO
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
PASI75	44.1 (36.5, 53.3)	55.4 (49.9, 61.6)	36.0 (26.4, 49.2)	46.2 (34.1, 62.6)
PASI90	25.0 (18.7, 33.4)	39.6 (34.2, 45.8)	22.7 (14.0, 36.8)	35.2 (22.3, 55.8)
PASI100	14.7 (9.8, 22.0)	30.6 (25.6, 36.5)	13.4 (6.9, 26.2)	28.2 (14.8, 53.8)
IGA ≤ 1	37.1 (29.7, 46.3)	53.8 (48.1, 60.3)	43.1 (30.7, 60.5)	60.3 (44.0, 82.6)

Covariates are held at their respective means for continuous variables, or at representative values for categorical variables (race = White, PsA (psoriatic arthritis) = None, gender = Male, line of therapy = 1 prior biologic); 95% confidence intervals (CI) are prediction intervals for an individual; IGA, Investigator's Global Assessment; \*Adjusted for age, gender, race, disease duration, psoriatic arthritis, line of therapy, and baseline outcome value